Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Sadry, S. A. & Drucker, D. J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9, 425–433, doi:nrendo.2013.47 (2013).
2. Holst, J. J. & Vilsboll, T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes. Metab. 15, 3–14, https://doi.org/10.1111/j.1463-1326.2012.01628.x (2013).
3. Roth, J. D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc. Natl. Acad. Sci. USA 105, 7257–7262, doi:0706473105 (2008).
4. Wang, Y. et al. Multifunctional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide Receptors. Angew. Chem. Int. Ed. 55, 12475–12478, https://doi.org/10.1002/anie.201606321 (2016).
5. Pan, C. Q. et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J. Biol. Chem. 281, 12506–12515, doi:M600127200 (2006).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献